Ross Moat, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), filed a Form 4 on November 3, 2026, disclosing option exercises and open-market sales of Class A Ordinary Shares on October 30 and November 2, 2026, all executed under a Rule 10b5-1 trading plan.

Key Highlights

  • 10b5-1 plan: All transactions were effected pursuant to a plan the reporting person executed on July 29, 2026.
  • October 30 exercises: Six tranches of share options were exercised on October 30, 2026, at exercise prices ranging from $10.76 to $18.06 per share.
  • November 2 exercises: Three additional option tranches were exercised on November 2, 2026, at exercise prices of $18.06, $21.77, and $22.89 per share.
  • October 30 sales: Seven tranches of Class A Ordinary Shares were sold on October 30, 2026, at weighted average prices ranging from $92.00 to $97.76 per share.
  • November 2 sales: Four tranches were sold on November 2, 2026, at weighted average prices ranging from $91.23 to $94.05 per share.
  • Remaining beneficial ownership: Following all reported transactions, Ross Moat directly held 10,294 Class A Ordinary Shares, according to the filing.

Ross Moat's Option Exercises and Share Sales Across Two Trading Days

According to the filing, Ross Moat, serving as Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, exercised multiple share option tranches on October 30 and November 2, 2026. On October 30, the options exercised carried exercise prices of $10.76, $11.10, $11.97, $12.97, $17.76, and $18.06, covering a total of six tranches. On November 2, three further tranches were exercised at prices of $18.06, $21.77, and $22.89. All exercises were coded "M," indicating exercises of in-the-money or at-the-money derivative securities, and all carried a derivative price of $0, as reported in Table II.

The filing reports that shares sold on October 30, 2026, were distributed across seven tranches with weighted average prices from $92.00 to $97.76. Each of these sales was executed in multiple trades through a broker-dealer, and the filing states that full price-by-price information is available to SEC staff upon request. On November 2, four additional sale tranches were reported at weighted average prices between $91.23 and $94.05, also executed through a broker-dealer in multiple trades. The filing notes that the sales price ranges underlying each weighted average are individually documented in the explanatory footnotes.

Kiniksa Pharmaceuticals International, plc is a clinical-stage biopharmaceutical company. The filing identifies the security as Class A Ordinary Shares listed on NASDAQ under the symbol KNSA. Following all reported transactions across both dates, the filing states that Ross Moat directly beneficially owned 10,294 Class A Ordinary Shares. Remaining derivative securities positions, including unexercised share options with expiration dates ranging to March 31, 2035, are also listed in Table II of the filing.

What Was Disclosed

The filing disclosed option exercises and open-market share sales by Kiniksa Pharmaceuticals International's Chief Operating Officer, Ross Moat, on October 30 and November 2, 2026, all conducted under a Rule 10b5-1 plan established on July 29, 2026, leaving 10,294 Class A Ordinary Shares in direct beneficial ownership.